Advance Search
ZHANG Baizhong, HAN Qing, MA Chunyuan. Investigation in serum minerals and bone disorder in patients with chronic kidney disease at stages 5 and 5D[J]. Journal of Clinical Medicine in Practice, 2021, 25(4): 89-92. DOI: 10.7619/jcmp.20200838
Citation: ZHANG Baizhong, HAN Qing, MA Chunyuan. Investigation in serum minerals and bone disorder in patients with chronic kidney disease at stages 5 and 5D[J]. Journal of Clinical Medicine in Practice, 2021, 25(4): 89-92. DOI: 10.7619/jcmp.20200838
shu

Investigation in serum minerals and bone disorder in patients with chronic kidney disease at stages 5 and 5D

  • 1.

    Department of Nephrology, Shuyang County People's Hospital in Jiangsu Province, Suqian, Jiangsu, 223600

  • 2.

    Department of Nephrology, The Ninth People's Hospital of Suzhou City in Jiangsu Province, Suzhou, Jiangsu, 215200

More Information
  • Received Date: December 11, 2020
  • Available Online: March 14, 2021
  • Published Date: February 27, 2021
    Graphical Abstract
    • Abstract
  •   Objective  To compare the serum minerals and bone disorder (MBD) between patients with chronic kidney disease (CKD) at stages 5 and 5D.
      Methods  Clinical data of 240 patients with end-stage renal disease were retrospectively analyzed. According to the condition of hemodialysis, the patients were divided into CKD5 group (treated without dialysis) and CKD5D group (treated with dialysis). The related indexes of serum minerals and bone disorder (serum calcium, phosphorus, whole parathyroid hormone, alkaline phosphatase, etc.) were compared between two groups, and the standard-reaching rates of serum calcium, phosphorus and parathyroid hormone were evaluated.
      Results  The levels of serum intact parathyroid hormone (iPTH), corrected serum calcium, calcium-phosphorus product and serum albumin in the CDK5D group were significantly higher than those in the CKD5 group, and the estimated glomerular filtration rate (eGFR) was significantly lower than that in the CKD5 group (P < 0.01). The incidence rates of hyperphosphatemia, hypocalcemia, hypercalcemia and high parathyroid hormone in the CKD5 and CDK5D groups were 83.75% and 91.25%, 31.25% and 17.50%, 1.88% and 30.00%, 37.50% and 63.75%, respectively.
      Conclusion  Patients with end-stage renal disease are accompanied by severe abnormalities of calcium, phosphorus and parathyroid hormone. Patients with CKD at stage 5 are characterized by high phosphorus, low calcium and high parathyroid hormone. The CKD-MBD status of patients with CKD at 5D stage do not improve due to hemodialysis, but become more serious, which are characterized by high levels of phosphorus, calcium and parathyroid hormone.
    • FullText(HTML)
    • References (13)
  • [1]
    MA Y C, ZUO L, CHEN J H, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease[J]. J Am Soc Nephrol, 2006, 17(10): 2937-2944. doi: 10.1681/ASN.2006040368
    [2]
    全国eGFR课题协作组. MDRD方程在我国慢性肾脏病患者中的改良和评估[J]. 中华肾脏病杂志, 2006(10): 589-595. doi: 10.3760/j.issn:1001-7097.2006.10.002
    [3]
    Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)[J]. Kidney Int Suppl, 2009(113): S1-130. http://www.ncbi.nlm.nih.gov/pubmed/19644521
    [4]
    FUKAGAWA M, YOKOYAMA K, KOIWA F, et al. Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder[J]. Ther Apher Dial, 2013, 17(3): 247-288. http://www.ncbi.nlm.nih.gov/pubmed/23735142
    [5]
    Kidney disease: improving global outcomes (KDIGO) CKD-MBD update work group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD)[J]. Kidney Int Suppl, 2017, 7(3): e1. doi: 10.1016/j.kisu.2017.10.001
    [6]
    ROUACHED M, EL KADIRI BOUTCHICH S, AL RIFAI A M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease[J]. Kidney Int, 2008, 74(3): 389-390.
    [7]
    马春园, 苑雪莹, 刘婧怡, 等. 慢性肾脏病-矿物质及骨代谢紊乱的单中心横断面研究[J]. 中华肾脏病杂志, 2015, 31(5): 333-338. doi: 10.3760/cma.j.issn.1001-7097.2015.05.003
    [8]
    MELAMED M L, EUSTACE J A, PLANTINGA L, et al. Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study[J]. Kidney Int, 2006, 70(2): 351-357. doi: 10.1038/sj.ki.5001542
    [9]
    TENTORI F, BLAYNEY M J, ALBERT J M, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the dialysis outcomes and practice patterns study (DOPPS)[J]. Am J Kidney Dis, 2008, 52(3): 519-530. doi: 10.1053/j.ajkd.2008.03.020
    [10]
    DEBOWSKA M, WOJCIK-ZALUSKA A, KSIAZEK A, et al. Phosphate, urea and creatinine clearances: haemodialysis adequacy assessed by weekly monitoring[J]. Nephrol Dial Transplant, 2015, 30(1): 129-136. doi: 10.1093/ndt/gfu266
    [11]
    COPLAND M, KOMENDA P, WEINHANDL E D, et al. Intensive hemodialysis, mineral and bone disorder, and phosphate binder use[J]. Am J Kidney Dis, 2016, 68(5): S24-S32. doi: 10.1053/j.ajkd.2016.05.024
    [12]
    ZHU J G, CHEN J B, CHENG B C, et al. Association between extreme values of markers of chronic kidney disease: mineral and bone disorder and 5-year mortality among prevalent hemodialysis patients[J]. Blood Purif, 2018, 45(1/2/3): 1-7. http://www.karger.com/?DOI=10.1159/000478972
    [13]
    VASSALOTTI J A, URIBARRI J, CHEN S C, et al. Trends in mineral metabolism: kidney early evaluation program (KEEP) and the national health and nutrition examination survey (NHANES)1999-2004[J]. Am J Kidney Dis, 2008, 51(4 Suppl 2): S56-S68. http://www.ncbi.nlm.nih.gov/pubmed/18359409
    • Related Articles

  • Related Articles

    [1]XU Hexi, SONG Hongqi, LIU Dianwen, LIU Shiju, YANG Huiju. Effect of silencing E26 transformation-specific sequence 4 on proliferation and migration of colon cancer cells by inhibiting nuclear factor-κB signaling pathway[J]. Journal of Clinical Medicine in Practice, 2025, 29(2): 38-41,47. DOI: 10.7619/jcmp.20243267
    [2]QIN Hang, FAN Shijie, LUO Zhicheng, LUO Hong. Value of TLR/NF-κB signaling axis in predicting bone infection in patients with open fractures[J]. Journal of Clinical Medicine in Practice, 2024, 28(21): 82-88. DOI: 10.7619/jcmp.20241773
    [3]HUANG Wei, WANG Xu, SHEN Zhimei, CUI Fei. Research progress on mechanism of action of stromal cell derived factor-1 in osteoporosis[J]. Journal of Clinical Medicine in Practice, 2022, 26(21): 144-148. DOI: 10.7619/jcmp.20222400
    [4]SUI Xiaolu, XU Yunpeng, ZHANG Yanzi, ZHANG Aisha, XIE Tingfei, YUAN Shuzhen, ZOU Jiefeng, ZENG Qicheng, CHEN Jihong. Mechanism of PI3K/AKT/NF-κB signaling pathway in rats with uric acid nephropathy[J]. Journal of Clinical Medicine in Practice, 2022, 26(18): 78-82. DOI: 10.7619/jcmp.20220022
    [5]SHEN Xiaoli, ZHUANG Xueming, QIAN Mengshu, MA Weixiong, CHEN Yueyang, LU Chaoming, FANG Xutao, WANG Shibo. MicroRNA-182-5p regulates the MAPK/NF-κB pathway by targeting MAPK1 to treat acute lung injury[J]. Journal of Clinical Medicine in Practice, 2022, 26(5): 79-85. DOI: 10.7619/jcmp.20214224
    [6]BAI Jingshu, BAI He, XU Wei. Effects of Compound Jingjie Fumigation Lotion on wound growth factors and inflammatory response in patients after anal fissure surgery[J]. Journal of Clinical Medicine in Practice, 2021, 25(9): 70-73. DOI: 10.7619/jcmp.20201974
    [7]ZHAO Chao, SONG Shulian, ZHOU Jie, JING Guoliang, ZHOU Yan, HAN Jingjing, HUA Fang. Effect of TLR4 antagonist on the secretion of inflammatory cytokines in microglia induced by Aβ1-42[J]. Journal of Clinical Medicine in Practice, 2016, (9): 1-5,13. DOI: 10.7619/jcmp.201609001
    [8]YUAN Lei. Influence of atorvastatin on serum inflammatory factors and adiponectin levels in patients with acute myocardial infarction[J]. Journal of Clinical Medicine in Practice, 2016, (5): 4-6,10. DOI: 10.7619/jcmp.201605002
    [9]GAO Shengli, XU Liangliang, PANG Zuoliang. Expression and clinical significance of Toll-like receptor 4 and nuclear Factor-kappaB in non-small cell lung cancer tissue[J]. Journal of Clinical Medicine in Practice, 2014, (9): 68-71. DOI: 10.7619/jcmp.201409019
    [10]LI Wei. Factors of ACS atorvastatin on blood lipid levels, serum inflammatory[J]. Journal of Clinical Medicine in Practice, 2013, (15): 56-58. DOI: 10.7619/jcmp.201315020

Catalog

    Get Citation
    PDF
    XML
    Article views (428) PDF downloads (15) Cited by()
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    © 2020 《实用临床医药杂志》编辑部

    Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807

    苏公网安备 32100302010246号

    Supported by: Beijing Renhe Information Technology Co., Ltd.   Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return